Opinion: Crowdfunding Falls Short for Gynecologic Cancer Patients
Oncology nurses can support patients facing financial toxicity by offering guidance on available resources and providing emotional support.
Related Articles
Durvalumab Plus BCG Boosts DFS in Non–Muscle-Invasive Bladder Cancer
Durvalumab added to BCG induction and maintenance improved disease-free survival vs BCG alone in high-risk non–muscle-invasive bladder cancer.
Panitumumab Improves Outcomes in RAS/BRAF Wildtype Colon Cancer
Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.
Pembrolizumab Combo Improves PFS in Platinum-Resistant Ovarian Cancer
KEYNOTE-B96 showed pembrolizumab-based therapy improved PFS and OS in PD-L1–positive platinum-resistant ovarian cancer.
Best Practices in Managing Talquetamab-Associated AEs in Myeloma
A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.
Allogeneic CT0596 Shows Early Activity, Safety in R/R Myeloma
CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.
Ribociclib Combo Produces Similar pCR to Chemo in HR+ Breast Cancer
Neoadjuvant ribociclib plus endocrine therapy showed pCR rates comparable to chemo in HR-positive, HER2-negative early breast cancer.
First-line Disitamab Vedotin/Toripalimab Ups Survival in HER2+ mUC
Disitamab vedotin with toripalimab improved PFS and OS over chemo in HER2-expressing metastatic urothelial carcinoma, per phase 3 trial interim analysis.
How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC
The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.
Ibrutinib/Nivolumab Yields Activity in Relapsed CNS Lymphoma
Three of 18 patients had remissions lasting over 2 years in a study of ibrutinib plus nivolumab for relapsed/refractory CNS lymphoma.
Retifanlimab Receives FDA Approval for Advanced Anal Cancer
Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.